Jupiter Topco LLC Makes New $139.16 Million Investment in Tyra Biosciences, Inc. $TYRA

Jupiter Topco LLC acquired a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,352,448 shares of the company’s stock, valued at approximately $139,161,000. Jupiter Topco LLC owned approximately 7.29% of Tyra Biosciences at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Janus Henderson Group PLC boosted its position in shares of Tyra Biosciences by 32.5% during the 1st quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company’s stock valued at $148,867,000 after purchasing an additional 955,147 shares in the last quarter. Commodore Capital LP increased its holdings in Tyra Biosciences by 226.3% in the second quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock worth $29,667,000 after purchasing an additional 2,150,000 shares in the last quarter. BlackRock Inc. acquired a new position in Tyra Biosciences in the second quarter valued at approximately $96,841,000. Farallon Capital Management LLC lifted its stake in Tyra Biosciences by 80.7% in the fourth quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock valued at $54,337,000 after buying an additional 923,000 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Tyra Biosciences by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company’s stock valued at $21,267,000 after buying an additional 118,492 shares during the period. 84.14% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Friday, July 17th. Wolfe Research began coverage on shares of Tyra Biosciences in a research report on Tuesday, May 19th. They set a “peer perform” rating on the stock. HC Wainwright reissued a “buy” rating and set a $45.00 target price on shares of Tyra Biosciences in a research note on Thursday, May 14th. Jefferies Financial Group restated a “buy” rating and issued a $42.00 price target on shares of Tyra Biosciences in a report on Wednesday, August 5th. Finally, Bank of America lifted their price target on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.90.

Tyra Biosciences Stock Down 1.8%

Shares of NASDAQ:TYRA opened at $26.22 on Thursday. Tyra Biosciences, Inc. has a twelve month low of $11.70 and a twelve month high of $40.65. The stock’s 50 day moving average is $29.62 and its 200-day moving average is $32.25. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -10.93 and a beta of 0.77.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Equities research analysts anticipate that Tyra Biosciences, Inc. will post -2.74 earnings per share for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.